本文へスキップ

Publication


2017
・Saitoh SI, Abe F, Kanno A, Tanimura N, Mori Saitoh Y, Fukui R, Shibata T, Sato K, Ichinohe T,
  Hayashi M, Kubota K, Kozuka-Hata H, Oyama M, Kikko Y, Katada T, Kontani K, Miyake K.
 TLR7 mediated viral recognition results in focal type I interferon secretion by dendritic cells.
 Nat Commun. 2017 Nov 17;8(1):1592.

・Walenna NF, Kurihara Y, Chou B, Ishii K, Soejima T, Itoh R, Shimizu A, Ichinohe T, Hiromatsu K.
 Chlamydia pneumoniae exploits adipocyte lipid chaperone FABP4 to facilitate fat mobilization and
  intracellular growth in murine adipocytes. Biochem Biophys Res Commun. (in press)

・Moriyama M, Takeyama H, Hasegawa H, Ichinohe T*. Induction of lung CD8+ T cell responses by
 consecutive inoculations of a poly(I:C) infleunza vaccine. Vaccine. 2017 Dec 4;35(48 Pt B):6620-6626.

・Koyanagi N, Imai T, Shindo K, Sato A, Fujii W, Ichinohe T, Takemura N, Kakuta S, Uematsu S, Kiyono H,
 Maruzuru Y, Arii J, Kata A, Kawaguchi Y. Herpes simplex virus-1 evasion of CD8+ T cell accumulation
 contributes to viral encephalitis. J Clin Invest. 2017 Oct 2;127(10):3784-3795.

・Moriyama M, Chino S, Ichinohe T*. Consecutive inoculations of influenza virus vaccine and poly(I:C)
 protects mice against homologous and heterologous virus challenge.
 Vaccine. 2017 Feb 15;35(7):1001-1007.

2016
・Moriyama M, Chen IY, Kawaguchi A, Koshiba T, Nagata K, Takeyama H, Hasegawa, H, Ichinohe T*.
 The RNA- and TRIM25-binding domains of infleunza virus NS1 protein are essential for suppression of
 NLRP3 inflammasome-mediated IL-1β secretion. J Virol. 2016 Mar 28;90(8):4105-14. [Link]

2015

・Chen IY, Ichinohe T*. Response of host inflammasomes to viral infection.
 Trends Microbiol. 2015 Jan;23(1):55-63.

2014
・Yoshizumi T, Ichinohe T, Sasaki O Otera H, Kawabata SI, Mihara K, Koshiba T. Influenza A
 virus protein PB1-F2 translocates into mitochondria via Tom40 channels and impairs innate
 immunity. Nat Commun. 2014 Aug 20;5:4713. doi: 10.1038/ncomms5713

・Yamazaki T, Ichinohe T*. Inflammasomes in antiviral immunity: clues for influenza vaccine
 development. Clin Exp Vaccines Res. 2014 Jan;3(1):5-11.

2013
Ichinohe T*, Yamazaki T, Koshiba T, Yanagi Y. Mitochondrial protein mitofusin 2 is required for
 NLRP3 inflammsome activation after RNA virus infection. Proc Natl Acad Sci U S A. 2013 Oct
 29;110(44):17963-8.

・Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition
 receptors in promoting CD8(+) T cell responses to influenza A virus.
 Nat Immunol.
2013 Jan 13;14(3):246-53.

2012
・Ito M, Yanagi Y, Ichinohe T*. Encephalomyocarditis virus viroporin 2B activates NLRP3
 inflammasome. PLoS Pathog. 2012 Aug;8(8):e1002857.

2011
・Komune N, Ichinohe T*, Ito M, Yanagi Y. Measles virus V protein inhibits NLRP3
 inflammsome-mediated interleukin-1β secretion. J Virol. 2011 Dec;85(24):13019-26.

Ichinohe T, Pang IK, Kumamoto Y, Peaper D, Ho JH, Murray TS, Iwasaki A. Microbiota  
 regulates immune defense against respiratory tract influenza A virus infection.
 Proc Natl Acad Sci U S A.
2011 March 29;108(13):5354-9.

Ichinohe T*, Yanagi Y. Recognition of viruses by inflammasomes. Fukuoka Igaku Zasshi. 
 2011 Feb;102(2):21-30. Review.

2010
Ichinohe T*. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and
 immunity: impact on vaccine design. Expert Rev Vaccines. 2010 Nov;9(11):1315-24. Review.

Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, Kawaguchi A, Suzaki Y, Odagiri T, Tashiro M,
 Takahashi H, Strayer DR, Carter WA, Chiba J, Tamura S, Sata T, Kurata T, Hasegawa H.
 Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with
 the highly pathogenic influenza A H5N1 virus. J Med Virol. 2010 Oct;82(10):1754-61.

Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular
  M2 ion channel. Nature Immunol. 2010 May;11(5):404-10.

・Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, Tashiro M, Hasegawa H. Zymosan enhances
 the mucosal adjuvant activity of poly(I :C) in a nasal influenza vaccine. J Med Virol. 2010
 Mar;82(3):476-84.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H,
 Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H. Induction of cross-protective
 immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom
 mycelia. J Med Virol. 2010 Jan;82(1):128-37.

2009
Ichinohe T*, Iwasaki A. Inflammasomes in viral infection. Uirusu. 2009 Jun;59(1):13-21.
 Review.

Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H. PolyI:polyC12U adjuvant-combined
 intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
 Vaccine. 2009 Oct 23;27(45):6276-9.

・Hasegawa H, Ichinohe T, Ainai A, Tamura S, Kurata T. Development of mucosal adjuvants for
 intranasalvaccine for H5N1 influenza viruses. Ther Clin Risk Manag. 2009 Feb;5(1):125-32.

Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A.Inflammasome recognition of influenza virus
 is essential for adaptive immune responses. J Exp Med. 2009 Jan 16;206(1):79-87.

-2008
Ichinohe T*, Iwasaki A, Hasegawa H. Innate sensors of influenza virus: clues to developing
 better intranasal vaccines. Expert Rev Vaccines. 2008 Nov;7(9):1435-45. Review.

・Kamijuku H*, Nagata Y*, Jiang X*, Ichinohe T*, Tashiro T, Mori K, Taniguchi M, Hase K,
 Ohno H,Shimaoka T, Yonehara S, Odagiri T, Tashiro M, Sata T, Hasegawa H, Seino KI.
 Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide,
 which can induce cross-protection against influenza viruses. Mucosal Immunol. 2008   
 May;1(3):208-18.

Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M,
 Takahashi H, Sawa H, Mitchell WM, Strayer DR, Carter WA, Chiba J, Kurata T, Sata T,
 Hasegawa H. Cross-protection against H5N1 influenza virus infection is afforded by intranasal
 inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis. 2007 Nov
 1;196(9):1313-20.

Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, Ninomiya A, Imai M, Itamura S,
 Odagiri T, Tashiro M, Chiba J, Sata T, Kurata T, Hasegawa H. Intranasal immunization
 with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against
 homologous and heterologous virus challenge. Microbes Infect. 2007 Sep;9(11):1333-40.

Ichinohe T, Nagata N, Strong P, Tamura S, Takahashi H, Ninomiya A, Imai M, Odagiri T, Tashiro
 M, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H. Prophylactic effects of chitin microparticles
 on highly pathogenic H5N1 influenza virus. J Med Virol. 2007 Jun;79(6):811-9.

・Hasegawa H, Ichinohe T, Tamura S, Kurata T. Development of a mucosal vaccine for influenza
 viruses: preparation for a potential influenza pandemic. Expert Rev Vaccines. 2007
 Apr;6(2):193-201. Review.

・Asahi-Ozaki Y, Itamura S, Ichinohe T, Strong P, Tamura S, Takahashi H, Sawa H, Moriyama M,
 Tashiro M, Sata T, Kurata T, Hasegawa H. Intranasal administration of adjuvant-combined
 recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
 Microbes Infect. 2006 Oct;8(12-13):2706-14.

・Maeda M, Sawa H, Tobiume M, Tokunaga K, Hasegawa H, Ichinohe T, Sata T, Moriyama M,
 Hall WW, Kurata T, Takahashi H. Tristetraprolin inhibits HIV-1 production by binding to genomic
 RNA. Microbes Infect. 2006 Sep;8(11):2647-56.

Ichinohe T, Watanabe I, Tao E, Ito S, Kawaguchi A, Tamura S, Takahashi H, Sawa H,
 Moriyama M, Chiba J, Komase K, Suzuki Y, Kurata T, Sata T, Hasegawa H. Protection against
 influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an
 adjuvant. J Med Virol. 2006 Jul;78(7):954-63.

・Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T,
 Tsunetsugu-Yokota Y, Katano H, takahashi H, Matsuda J, Sata T, Kurata T, Nagashima K, hall
 WW. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human
 T-lymphotropic virus type I. Nat Med. 2006 Apr;12(4):466-72.

Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J,
 Kurata T, Sata T, Hasegawa H. Synthetic double-stranded RNA poly(I:C) combined
 with mucosal vaccine protects against influenza virus infection. J Virol. 2005 Mar;79(5):2910-9.

・Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H,
 Chiba J, Kurata T, Sata T. Protection against influenza virus infection by intranasal
 administration of hemagglutinin vaccine with chitin microparticles as an adjuvant. J Med Virol.
 2005 Jan;75(1):130-6.

・Watanabe I, Ross TM, Tamura S, Ichinohe T, Ito S, Takahashi H, Sawa H, Chiba J, Kurata T,
 Sata T, Hasegawa H. Protection against influenza virus infection by intranasal administration of
 C3d-fused hemagglutinin. Vaccine. 2003 Nov 7;21(31):4532-8.